Abstract: The present invention provides a novel alkylating agent specifically binding to the genetic mutation site of a driver oncogene. There are provided are a complex formed by binding an alkylating agent to a pyrrole imidazole polyamide specifically binding to the genetic mutation site of a driver oncogene, a driver oncogene mutation-specific alkylating agent comprising the aforementioned complex, and a pharmaceutical composition comprising the aforementioned complex.

Abstract: The invention provides compositions and methods useful for the depletion of cells, such as CD45+, CD135+, CD34+, CD90+, and/or CD110+ cells, and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cancer cells or autoimmune cells.

Abstract: Disclosed are antibodies and antibody drug conjugates having an Fc region with substitutions resulting in essentially a silent Fc region. The antibodies and antibody drug conjugates described herein are useful for the depletion of cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting, e.g., a population of CD45+ or CD117+ cancer cells or CD45+ autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.

Abstract: The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds humanSTEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2.

Abstract: Provided herein are polymeric particles and compositions (i.e., “backpacks”) that can adhere to cells and provide delivery of payload immunomodulatory agents to those cells. For examples, the particles can adhere to macrophages and/or monocytes and release cytokines that promote an M1 or M2 phenotype to improve therapeutic efficacy of the cells.

Abstract: The present invention relates to a lipid nanoparticle complex comprising an aptide fused with a cell penetrating material and a use thereof. Particularly, the lipid nanoparticle complex according to the present invention contains long-chain and short-chain phospholipids, and comprises an aptide fused with a cell-penetrating material. In particular, when the long-chain and short-chain phospholipids are included in a specific molar ratio, the lipid nanoparticle complex exhibits a discoid structure. In addition, when the lipid nanoparticle complex comprises the aptide for STAT protein as an aptide, it has superior cell or skin cell permeability, delivers the aptide to the dermal layer to show treatment effect on psoriasis without side effects, inhibits the expression of fibrosis-related genes increased by TGF-?, and attenuates symptoms of pulmonary fibrosis in in vivo model. Thus, the lipid nanoparticle complex according to the present invention can be effectively used as a carrier for various aptides.

Abstract: In various embodiments a polyrotaxane carrier for in vivo delivery of a nucleic acid is provided. In certain embodiments the carrier comprises: a multi-arm polyethylene glycol (PEG) backbone comprising at least three arms; at least one cyclic compound having a cavity, where an arm of said multi-arm PEG backbone is threaded into the cavity of said cyclic compound forming an inclusion complex; a bulky moiety capping the terminal of the arm(s) threaded into said cyclic compound where said moiety inhibits dethreading of the cyclodextrin from the arm(s) of said backbone; and where at least one arm of said PEG backbone is free of cyclic compounds; and where said carrier has a net positive charge.

Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PCSK9 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of hypercholesterolemia or a condition associated therewith.

Abstract: This invention relates to polynucleotides encoding mini-dystrophin proteins, viral vectors comprising the same, and methods of using the same for delivery of mini-dystrophin to a cell or a subject.

Abstract: An isolated mRNA sequence for expression of one or more polypeptides within one or more target organs, the sequence comprising at least one coding sequence which codes for the at least one polypeptide, at least a first untranslated region (UTR) sequence and a plurality of micro-RNA (miRNA) binding site sequences. Each oft he miRNA binding site sequences is located within, immediately 5? to or immediately 3? to, the first UTR sequence; and the miRNA binding site sequences allow for differential expression of the coding sequence in at least a first and a second cell type within the target organ or organs Methods for using the composition are provided, particularly in treatment of disease, such as cancer of the liver, brain, lung, breast, pancreas, colon and kidney.

Abstract: A method that may be used in the imaging of tissues or subjects includes flushing a tissue or subject with a solution, preserving the tissue or subject, and then introducing an imaging contrast agent into the tissue or subject. After these actions, the tissue or subject may be imaged.

Abstract: Methods of detecting an aldehyde-containing compound in a subject or in a sample from a subject are described herein, comprising administering an aldehyde-binding compound of Formula I to the subject, or combining such a compound with the sample; and detecting the product of the compound of Formula I and the aldehyde-containing compound. Detection of the product may involve imaging, such as MRI, CEST-MRI or positron emission tomography (PET) imaging; or may involve fluorescence or an electrochemical detection method. Biologically relevant aldehydes detected according to the described method can be used to monitor conditions such as brain injury, neurodegenerative disorders such as Alzheimer's disease, diabetes, heart disease, and cancer.

Abstract: The present invention relates to the RRR/SSS pair of enantiomers of the of Gd(PCTA-tris-glutamic acid), the single enantiomers of the pair, the pharmaceutically acceptable salts thereof, their amide derivatives, and compositions comprising at least 50% of these compounds.

Abstract: The invention relates to therapeutic nanobiologic compositions and methods of treating patients who have had an organ transplant, or who suffer from atherosclerosis, arthritis, inflammatory bowel disease including Crohn's, autoimmune diseases including diabetes, and/or autoinflammatory conditions, or after a cardiovascular events, including stroke and myocardial infarction, by inhibiting trained immunity, which is the long-term increased responsiveness, the result of metabolic and epigenetic re-wiring of myeloid cells and their stem cells and progenitors in the bone marrow and spleen and blood induced by a primary insult, and characterized by increased cytokine excretion after re-stimulation with one or multiple secondary stimuli.

Abstract: The present invention provides sodium saccharin bound with a ligand, derivatives thereof, and a process for preparation thereof. According to the present invention, there is provided a compound which is specifically bonded to hypoxic tumors. Specifically, the compound having sodium saccharin (SAC) bound with a ligand compound, or derivatives thereof can be applied to a contrast agent for cancer diagnosis.

Abstract: A method of treating a cancer in a mammalian subject afflicted with the cancer, includes administering to the subject an immune checkpoint inhibitor, and administering to the subject a pentaaza macrocyclic ring complex corresponding to the formula (I) below, prior to, concomitantly with, or after administration of the immune checkpoint inhibitor, to increase the response of the cancer to the immune checkpoint inhibitor.

Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.

Abstract: A method and apparatus for conditioning an RV/Marine toilet bowl seal are disclosed, including providing an apparatus comprising a plug comprising a handle portion; and a solid foam coupled to the handle portion; wherein the handle portion is configured to allow a user to insert or remove the solid foam of the plug from a discharge opening of an RV/Marine toilet bowl; and wherein the solid foam is configured to make contact with at least a portion of the RV/Marine toilet bowl seal; pouring a conditioner into the discharge opening of the RV/Marine toilet bowl; inserting the plug into the discharge opening of the RV/Marine toilet bowl such that the solid foam contacts with at least a portion of the RV/Marine toilet bowl seal; and rotating the plug by about a quarter of a turn. Other embodiments are described and claimed.

Abstract: A free-standing device for releasing fragrances includes a hollow external cylinder having an inner surface engaging the outer surface of an internal cylinder, the internal cylinder being closed. The inner surface of the external cylinder and the outer surface of the internal cylinder are fully at contact with each other. If open, the internal cylinder projects beneath the external cylinder, allowing the user to insert it into a support having a resting surface and an upper projection perforated centrally. The upper projection has aeration holes, sliding the internal cylinder with respect to the external cylinder exposing a portion of the inner surface of the external cylinder and the outer surface of the internal cylinder. A perfumed scent is applied on the inner surface of the external cylinder and/or on the outer surface of the internal cylinder; the internal cylinder having break-lines for removing portions of the internal cylinder.

Abstract: Systems and methods for reducing airborne contaminants are provided. An air treatment system may include an opening and a filter assembly, a fan coupled to a sanitizing chamber, and an exhaust portion configured to release airflow that has passed through the sanitizing chamber. The fan may be configured to generate an airflow of filtered air through the sanitizing chamber, and the sanitizing chamber may include at least one bend having a total bend angle of at least 90 degrees and at least one straight channel with an array of ultraviolet (UV) light emitting diodes (LEDs) configured to irradiate the airflow with UV radiation. A ratio of a total length of the sanitizing chamber to a cross-sectional area of the sanitizing chamber may be at least 25.

Abstract: An air treatment system comprising a plurality of excimer lamps, said system is arranged such that at least 90% of air flowing through the air treatment system will be exposed, to photons emitted from the excimer lamps, whereby the excimer lamps provides a large emission area in which high energy ultraviolet (UV) photons is provided at low cost. The photons will upon contact with contaminants in the air break down said contaminants through the process of photolysis, which is highly effective at removing different organic compounds, e.g. odours from the air. The system can be designed with different wavelengths, making the system a simple and inexpensive air treatment system both for use in large area industrial applications and for domestic uses.

Abstract: The invention is a non-hydrated, keratin wound dressing film comprising a fraction of keratins isolated from a solution of extracted keratins. Said fraction enables the formation of film with greater flexibility that can be achieved in film made from the unfractionated keratin extract. Also disclosed is a process of forming wound dressings and a method of obtaining said keratin fraction from an extract of human hair or other keratin raw materials.

Abstract: The invention relates to a device for adsorbing odours comprising an absorbent layer and an adsorbent layer, said adsorbent layer being provided with a material permeable to volatile organic compounds (VOCs) and an adsorbent particulate filler comprising at least one spice. Such a device is particularly useful for adsorbing and masking body odours.

Abstract: Provided are methods related to the treatment of epidermal wounds via topical application of a cannabinoid such as, for example, cannabidiol, cannabinol, tetrahydrocannabinol, and cannabigerol. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: A haemostatic material that is effective at controlling the flow of blood from both standard and coagulopathic wound injuries that maintains a reduced compression time minimising the requirement for resuscitation fluids, and being easy and safe to use.

Abstract: There are provided tissue repair laminates containing at least two biodegradable polyurethane foam layers and a polyurethane structural layer. The biodegradable polyurethane is derived from biodegradable polyols. The laminates resist shrinkage under in vivo conditions and possess desirable mechanical properties such as high tensile strength. The laminates find use in, for example, the repair of tissue or muscle wall defects.

Abstract: Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a silk fibroin component.

Abstract: The present disclosure provides tissue products produced from adipose tissues, as well as methods for producing such tissue products. The tissue products can include acellular tissue matrices for treatment of a breast.

Abstract: A percutaneous minimally-invasive procedure to prevent a potential fracture in an osteoporotic vertebra of an osteoporotic patient who has no history of vertebral fracture is provided by minimally-invasively injecting a non-dispersive, biocompatible and resorbable calcium-based cement paste into the osteoporotic vertebral body.

Abstract: Compositions and blends of biopolymers and bio-acceptable polymers are described, along with the use of benign solvent systems to prepare biocompatible scaffolds and surgically implantable devices for use in supporting and facilitating the repair of soft tissue injuries.

Abstract: The present invention relates generally to tissue forms useful as grafts or implants and derived from membranous tissue. The tissue forms may contain viable endogenous cells. The tissue forms may be sheets or mini sheets, each having quadrilateral, circular, polygonal, or irregular shapes. The sheet tissue form may have a generally quadrilateral shape, with an average length of about 1 to about 20 centimeters and an average width of about 1 to about 20 centimeters. The mini sheet tissue form may have a generally quadrilateral shape, with an average length of about 0.5 to about 9 millimeters and an average width of about 0.5 to about 9 millimeters. A mixture of the mini sheet tissue form and a liquid, such as cryopreservation fluid, saline or buffer solution, is flowable, which means the mixture will pass through a luer-slip tip syringe, or a gauge needle.

Abstract: The present invention relates to a built-in bio-sleeve and preparation method and use thereof. In order to provide a suitable built-in bio-sleeve material for dorsal nerve isolation surgery and penis enlargement surgery, a novel acellular allogeneic dermal matrix material is prepared in the present invention, which is manufactured into a built-in bio-sleeve for the treatment of premature ejaculation and short and small penis. The acellular allogeneic dermal matrix or the built-in bio-sleeve of the present invention is used for dorsal nerve isolation surgery, penis enlargement or lengthening surgery without cutting off the dorsal nerve, thereby avoiding the probability of psychological erectile dysfunction caused by the patient's worry about cutting off the dorsal nerve.

Abstract: A method for fabricating a cornea includes affixing a frame to at least one cell culture insert comprising a generally cylindrical structure having a proximal end and a distal end, a base disposed at the proximal end, and a porous membrane disposed between the proximal end and the distal end; affixing a dome-shaped member to the porous membrane within the frame, the dome-shaped member comprising a crown, a dome base, and a surface connecting the crown and the dome base; depositing a material comprising a matrix-forming compound on the frame such that the crown and at least a portion of the surface of the dome-shaped member is coated with the material comprising the matrix-forming compound; and removing the dome-shaped member to produce a fabricated cornea attached to the frame. A system for fabricating a cornea and a cornea scaffold are also described herein.

Abstract: The present invention relates to a composition comprising stem cells, a cell culture medium and a polyacrylamide hydrogel (PAAG), wherein the PAAG contains less than 0.02% Wmonomer/Wtotal PAAG] of a N-hydroxyethyl acrylamide (HEA) side chain. The invention also relates to the process of making the composition. In particular, the present invention relates to the composition, wherein the composition is administered by injection and wherein it is used in medicine, in particular for use in prevention and/or treatment of e.g. tendon injury in a mammal, arthritis in a mammal or arthropathy in a mammal. Tendon injury, arthritis or arthropathy may occur in a human, a racing animal or a companion animal.

Abstract: The present invention relates to a method for preparing of a nerve conduit using bio-printing technology and a nerve conduit prepared by the same, and it can easily prepare a nerve conduit by simulating a nerve bundle and nerve tissue, and the like, by three-dimensionally printing bio-ink comprising a neuronal regeneration material on one side of a porous polymer scaffold.

Abstract: An improved new method of making a multi-component implant comprising a solid hydrogel, a porous hydrogel, and a porous rigid base suitable for implantation into a mammal, to treat, repair or replace defects and/or injury biological tissue as well as the implant made from the improved method. The invention also includes an improved method for making devices, constructs, and materials comprising a hydrogel and a porous rigid material. The invention also includes a mold and kits for performing the methods.

Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.

Abstract: The present invention provides polymeric fiber scaffolds, methods and devices suitable for fabricating such polymeric fiber scaffolds, and uses thereof for wound healing.

Abstract: Disclosed is a medical device exhibiting superior lubricating property and durability (lubrication retaining property), the medical device comprising a substrate layer, an adhesive layer formed on at least a portion of the substrate layer, comprising a hydrophilic copolymer comprising a structural unit derived from a polymerizable monomer (A) having a sulfobetaine structure, a structural unit derived from a polymerizable monomer (B) having at least one group selected from the group consisting of a sulfonic acid group, sulfuric acid group, sulfurous acid group, and salts thereof, and a structural unit derived from a polymerizable monomer (C) having a photoreactive group, and a surface lubricious layer formed on at least a portion of the adhesive layer, comprising a hydrophilic polymer dissolvable in a solvent capable of dissolving or swelling the hydrophilic copolymer.

Abstract: There is described a bioresorbable metal alloy which is particularly suitable for the formation of bioresorbable medical devices, for example stents. The metal alloy essentially comprises 3.2 to 4.8% by weight lithium, 0.5 to 2.0% by weight yttrium; and the balance being magnesium, in addition to any trace elements. The metal alloy can be drawn into a wire which can be shaped into a stent scaffold. The stent can be produced using one or more stent scaffolds together with one or more bioresorbable polymer connectors, for example formed from PLGA.

Abstract: A chronically implanted medical device is disclosed that has an outermost layer formed from a conjugate of a polymer with lipoic acid, the conjugate having free 1,2-dithiolane groups. It is contemplated that this layer scavenges reactive oxygen species, i.e. acts as an antioxidant, and thus reduces inflammation and other adverse effects around the implant itself.

Abstract: Implantable medical devices are provided. In one embodiment, a device includes a body having an external surface defining an outer profile of the device. The body includes a porous matrix including a series of interconnected macropores defined by a plurality of interconnected struts each including a hollow interior. A filler material substantially fills at least a portion of the series of interconnected macropores. The external surface of the body includes a plurality of openings communicating with the hollow interior of at least a portion of the plurality of interconnected struts. In a further aspect of this embodiment, the external surface includes exposed areas of the filler material and porous matrix in addition to the exposed openings. In another aspect, the porous matrix is formed from a bioresorbable ceramic and the filler material is a biologically stable polymeric material. Still, other aspects related to this and other embodiments are also disclosed.

Abstract: In some embodiments, a negative pressure wound therapy system can detect and classify one or more operational conditions, including detection of a wound bleeding. The system can react to detection of blood by providing an indication, reducing the intensity or stopping therapy, releasing negative pressure, etc. In certain embodiments, the system can detect one or more additional operational conditions, such as change in vacuum pressure, gas leak rate change, exudate flow rate change, water flow rate change, presence of exudate, presence of water, etc. The system can detect and distinguish between different operational conditions and provide indication or take remedial action.

Abstract: The present device includes a tube-free, cordless, battery-powered suction device. Activation of the device can be intermittent via depression of a trigger that allows for instantaneous awareness of fluid volume loss. In an example, the present device is a lightweight, suction hand unit including an indwelling impeller motor, removable and rechargeable lithium ion battery pack that is hermetically sealed, removable fluid reservoirs, a variety of replaceable nozzle tips, and an ULPA filter.

Abstract: An apparatus (10) for controlling flow of fluid from a wound site of a patient including a cavity (28) connectable to a wound site and a reservoir (16). The cavity (28) may have a first deformed state, and a second state in which it is not deformed or less deformed than in the first state. The cavity (28) may be adapted to manage fluid flow between the wound site and the reservoir (16) during transition of the cavity (28) between the first state and the second state. An actuator element (64) of the apparatus (10) may be adapted to operate on the chamber (28) to transition the cavity (28) from the second state to the first state.

Abstract: The illustrative embodiments described herein are directed to an apparatus, system, and method for storing liquid from a tissue site. The apparatus may include a drape having an aperture, and a fluid pouch coupled to the drape such that the fluid pouch is in fluid communication with the aperture. In one embodiment, the fluid pouch is operable to transfer reduced pressure to the aperture such that the liquid from the tissue site is drawn into the fluid pouch. The fluid pouch may have a cavity that stores the liquid that is drawn from the tissue site. In another embodiment, the fluid pouch may include at least one baffle. The fluid pouch may also include a fluid channel at least partially defined by the at least one baffle. The fluid channel may be operable to store liquid from the tissue site when reduced pressure is applied through the fluid channel.

Abstract: A pump catheter for the directed pulsatile conduction of blood includes a proximal section and a distal section which has an expandable pump chamber and a tube section arranged distally from the pump chamber. The tube section has an outlet opening. An inlet element having at least one inlet opening is arranged between the proximal section and the pump chamber and the inlet element and the pump chamber are geometrically spaced apart by a coupling element.

Abstract: A connection system for an implantable blood pump including a pump housing having an impeller disposed therein and a motor housing including a motor disposed therein, the motor housing spaced a distance from the pump housing. A flexible outer sheath couples the pump housing to the motor housing, the outer sheath defining a maximum total length between 7 and 10 centimeters. An inner shaft is coaxial with the outer sheath and couples the motor to the impeller.

Abstract: There is provided an intravascular blood pump for insertion into a patient's body. The system comprises a slotless motor having p magnet pole pairs and n phases, where p is an integer greater than zero, and n is an integer ?3. The motor comprises a stator winding having 2np coils wound to form two coils per phase per magnet pole pair such that a coil from each phase is circumferentially arranged next to a coil from a different phase in a sequential order of phase, the arrangement repeated along the stator winding such that each coil spans 360°/(2np) about the cross section of the stator winding. The motor also comprises a permanent magnet rotor supported for rotation and configured to generate a magnetic flux for interaction with the stator winding. The two coils per phase per magnet pole pair are connected in series.

Abstract: A blood pump comprises a pump casing having a blood flow inlet and a blood flow outlet, and an impeller arranged in said pump casing and rotatably supported in the pump casing by a bearing so as to be rotatable about an axis of rotation. The impeller has blades for conveying blood from the blood flow inlet to the blood flow outlet. The bearing comprises at least one stationary bearing portion coupled to the pump casing and having a stationary bearing surface that faces radially outwards. The bearing further comprises a rotating bearing surface interacting with the stationary bearing surface to form the bearing, wherein the rotating bearing surface faces radially inwards and is formed on an exposed radially inner edge of the blades. The blades are designed to draw blood deposit on the stationary bearing surface in a radially outward direction.